Home
NewsNews3billion has gone on to launch the Family Insight Test using WES and WGS analysis aimed at targeting couples who cannot get pregnant for no apparent reason, helping them discover hidden genetic factors affecting fertility.
3billion, a company that uses artificial intelligence to diagnose rare genetic diseases, said on March 31, 2026, that it has launched the Family Insight Test, a precision genomic diagnostic test for families. Family Insight makes use of WES and WGS analysis to test genetic roots of unexplained infertility with whole exome sequencing - WES and whole genome sequencing - WGS analysis in order to help people and families who have had problems during pregnancy and childbirth or who have a family history of genetic disorders.
3billion has mostly been looking for genetic causes in rare disease patients who have symptoms that lack a clear cause. The company's proprietary AI-based genetic variant interpretation technology is now available to families through the new service. This lets users check ahead of time if a disease is likely to happen.
Taking into account the genetic roots of unexplained infertility, the Family Insight Test is aimed at high-risk groups, such as couples who can't get pregnant for no apparent reason or who have had multiple miscarriages, cases where getting patient samples is hard and family-based alternative diagnosis is needed, and people with a family history of genetic diseases who want to know their own risk ahead of time.
The service also offers Carriership Finding, which looks at differences in autosomal recessive and X-linked disorders across about 2,000 important genes. This looks at the risk of passing on genetic diseases to children even when parents don't show any signs, thereby supporting family planning based on data.
With this launch, 3billion wants to reach more customers than just the genetics specialist-centred market. They want to reach large obstetrics and gynaecology hospitals, in vitro fertilization - IVF clinics, and family planning counselling centres.
Before the service went live, the company ran pilot tests in parts of the Middle East and Africa where a lot of people marry their cousins. This indicated that there was a need for genetic risk management and that the market was viable. The company plans to offer the service in areas with high birth rates, such as Asia and South America, based on these results. Keum Chang-won, CEO of 3billion, said, "We have extended the AI genetic variant interpretation technology accumulated through rare disease diagnosis beyond individuals to the family unit. "Our goal is to reduce genetic uncertainty and support safer family planning."
3billion plans to grow beyond rare disease diagnosis into precision medicine that helps individuals and families make decisions about their genetic risk. This will go on to strengthen its position as an AI genomic data platform company.
India's Central Drugs Standard Control Organisation has overhauled CDSCO IVF reagent sale norms, directing that all ART media, culture solutions, and reagents be supplied exclusively to clinics registered under the ART (Regulation) Act and Surrogacy (Regulation) Act. The move targets a growing unlicensed supply chain feeding an estimated 40–50% of India's 2,000-plus IVF centres.
Abu Dhabi University and FertiClinic Group have joined forces to establish the FertiClinic Reproductive Research Lab, an advanced reproductive research lab in Abu Dhabi housing IVF, andrology, and cryopreservation facilities. The partnership supports UAE national priorities, bridges academic and clinical expertise, and advances fertility innovation across the region.
NHS Kent and Medway has overhauled its fertility funding policy in a move that sees NHS cuts IVF access for thousands of patients. Effective 1 April 2026, the eligible age ceiling drops from 40 to 38, funded cycles fall from two to one, and embryo transfers are capped at two.
ASEAN's First Telemedicine IVF by Inspire IVF introduces a new era of remote fertility care. Combining AI technology with expert consultation, the platform enables global access, real-time monitoring, and personalised treatment planning, positioning Thailand as a leading hub for fertility services and advancing digital transformation in reproductive healthcare.
CSG.BIO has gone ahead with the acquisition of Hanabusa IVF, Asian Egg Bank, thereby making it a world leader in reproductive medicine and cutting-edge clinics with enhanced patient reach and advanced laboratory capabilities.
Wisconsin lawmakers from both parties are proposing bills to reduce IVF treatment costs. Republicans suggest a $5,000 tax credit for expenses, while Democrats want mandatory insurance coverage. With IVF cycles costing $20,000-$30,000 and 170,000 residents facing infertility, both parties seek affordable solutions through different approaches.
The AI-specialized Infertility Center, which is the largest in Asia, is open in Magok, Seoul and has begun its full-scale medical services from November 17 thereby marking the new era when it comes to fertility in the region.
